Brain pharmacokinetics of mono- and bispecific amyloid-β antibodies in wild-type and Alzheimer’s disease mice measured by high cut-off microdialysis

BACKGROUND: Treatment with amyloid-β (Aβ) targeting antibodies is a promising approach to remove Aβ brain pathology in Alzheimer's disease (AD) and possibly even slow down or stop progression of the disease. One of the main challenges of brain immunotherapy is the restricted delivery of antibod...

Descripción completa

Detalles Bibliográficos
Autores principales: Julku, Ulrika, Xiong, Mengfei, Wik, Elin, Roshanbin, Sahar, Sehlin, Dag, Syvänen, Stina
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9743601/
https://www.ncbi.nlm.nih.gov/pubmed/36510227
http://dx.doi.org/10.1186/s12987-022-00398-w

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9743601/
https://www.ncbi.nlm.nih.gov/pubmed/36510227
http://dx.doi.org/10.1186/s12987-022-00398-w

Ejemplares similares